TW201109029A - Vaccine therapy for choroidal neovascularization - Google Patents

Vaccine therapy for choroidal neovascularization Download PDF

Info

Publication number
TW201109029A
TW201109029A TW099118513A TW99118513A TW201109029A TW 201109029 A TW201109029 A TW 201109029A TW 099118513 A TW099118513 A TW 099118513A TW 99118513 A TW99118513 A TW 99118513A TW 201109029 A TW201109029 A TW 201109029A
Authority
TW
Taiwan
Prior art keywords
amino acid
peptide
sequence
leucine
acid sequence
Prior art date
Application number
TW099118513A
Other languages
English (en)
Chinese (zh)
Inventor
Motokazu Tsujikawa
Yusuke Nakamura
Takuya Tsunoda
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of TW201109029A publication Critical patent/TW201109029A/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60N—SEATS SPECIALLY ADAPTED FOR VEHICLES; VEHICLE PASSENGER ACCOMMODATION NOT OTHERWISE PROVIDED FOR
    • B60N2/00—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles
    • B60N2/02—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable
    • B60N2/22—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable
    • B60N2/225—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms
    • B60N2/2252—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms in which the central axis of the gearing lies inside the periphery of an orbital gear, e.g. one gear without sun gear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Mechanical Engineering (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Transportation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW099118513A 2009-06-11 2010-06-08 Vaccine therapy for choroidal neovascularization TW201109029A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009140363 2009-06-11

Publications (1)

Publication Number Publication Date
TW201109029A true TW201109029A (en) 2011-03-16

Family

ID=43308696

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099118513A TW201109029A (en) 2009-06-11 2010-06-08 Vaccine therapy for choroidal neovascularization

Country Status (14)

Country Link
US (1) US8975229B2 (enExample)
EP (1) EP2440226A4 (enExample)
JP (1) JP5688587B2 (enExample)
KR (1) KR20120038419A (enExample)
CN (1) CN102802654A (enExample)
AU (1) AU2010259797B2 (enExample)
BR (1) BRPI1013025A2 (enExample)
CA (1) CA2764562A1 (enExample)
IL (1) IL216402A0 (enExample)
MX (1) MX2011012659A (enExample)
RU (1) RU2555345C2 (enExample)
SG (2) SG10201403109VA (enExample)
TW (1) TW201109029A (enExample)
WO (1) WO2010143435A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289532A1 (en) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
ES2405763T3 (es) * 2007-02-16 2013-06-03 Oncotherapy Science, Inc. Vacunoterapia para la neovascularización coroidea
FR2990352A1 (fr) 2012-05-10 2013-11-15 Univ Paris 13 Composition immunogene comprenant un peptide derive du vegf et ses utilisations
CN110612115A (zh) * 2017-05-19 2019-12-24 学校法人庆应义塾 针对脑神经疾病的肽疫苗和肽疫苗组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6348333B1 (en) 1997-01-17 2002-02-19 Toa Gosei Co., Ltd. VEGF-binding KDR polypeptide
JP4405597B2 (ja) 1997-06-18 2010-01-27 メルク エンド カムパニー インコーポレーテッド ヒト受容体型チロシンキナーゼkdr
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
WO2001012809A2 (en) 1999-08-13 2001-02-22 Crucell Holland B.V. Heterodimeric vegf variants used for inhibiting angiogenesis
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002362461A1 (en) 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
EP2267023B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
SI1539157T1 (sl) 2002-09-18 2013-11-29 Trustees Of The University Of Pennsylvania Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
ES2687645T3 (es) 2003-10-27 2018-10-26 Merck Sharp & Dohme Corp. Método de diseño de ARNip para el silenciamiento de genes
JP2006215988A (ja) * 2005-02-07 2006-08-17 Ntt Docomo Kansai Inc 認証システム、携帯端末装置及び認証方法
EP2289532A1 (en) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
JP2006315988A (ja) 2005-05-11 2006-11-24 Mototake Shimizu ケモカイン産生誘導効果を有する血管新生阻害物質
ES2405763T3 (es) 2007-02-16 2013-06-03 Oncotherapy Science, Inc. Vacunoterapia para la neovascularización coroidea
JP5272134B2 (ja) 2007-06-14 2013-08-28 オンコセラピー・サイエンス株式会社 Smyd3によるvegfr1のメチル化調整因子を同定する方法
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌

Also Published As

Publication number Publication date
JP2012529423A (ja) 2012-11-22
KR20120038419A (ko) 2012-04-23
EP2440226A1 (en) 2012-04-18
BRPI1013025A2 (pt) 2016-04-05
EP2440226A4 (en) 2013-09-18
MX2011012659A (es) 2011-12-16
IL216402A0 (en) 2012-01-31
SG176737A1 (en) 2012-01-30
CA2764562A1 (en) 2010-12-16
SG10201403109VA (en) 2014-10-30
WO2010143435A1 (en) 2010-12-16
JP5688587B2 (ja) 2015-03-25
RU2012100241A (ru) 2013-07-20
AU2010259797A1 (en) 2011-12-08
US20120156233A1 (en) 2012-06-21
CN102802654A (zh) 2012-11-28
US8975229B2 (en) 2015-03-10
RU2555345C2 (ru) 2015-07-10
AU2010259797B2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
US20240033340A1 (en) Novel vaccines against hpv and hpv-related diseases
US20210283242A1 (en) Immune-mediated coronavirus treatments
JP6266811B2 (ja) 血管新生病の免疫療法
CN111565746A (zh) 用于预防和治疗多种黄病毒的mhc i类相关肽
TW202045204A (zh) 安全投予磷酸化Tau胜肽疫苗的方法
US11426457B2 (en) MHC class I associated peptides for prevention and treatment of zika virus
CN113491766A (zh) 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
AU2010259797B2 (en) Vaccine therapy for choroidal neovascularization
JP5470558B2 (ja) 脈絡膜新生血管のワクチン療法
US20230203103A1 (en) Diagnosis, prevention and treatment of coronavirus infection
WO2007081301A2 (en) Methods and compositions related to the identification of a novel il-12 inducing protein isolated from toxoplasma gondii
CA2548483A1 (en) Induction of antiviral neutralizing antibodies in humans and animals
HK1134449B (en) Vaccine therapy for choroidal neovascularization